Fig. 4
Cell stiffness-mediated increases in cellular ATP:ADP ratio and glucose uptake are correlated with matrix deformation. a Model predictions for energy requirements for migration into tracks of varying size with increasing cell stiffness. b–d Model predictions for energy requirements for migration (b), cell elongation (c), and track displacement (d) as a function of cell stiffness in 7 μm microtracks. e Normalized PercevalHR ratio with increasing confinement following pharmacological treatments and siCav1 knockdown (n = Ctrl: 111, 91, 118; Rho+: 111, 92, 107; CL-A: 121, 95, 100; Y27: 127, 117, 135; ML7: 114, 95, 107; MβCD: 116, 105, 123; siCtrl: 63, 49, 53; siCav1: 68, 46, 55 cells for 15, 12, 7 μm microtracks). f 2-NBDG uptake with increasing confinement following pharmacological treatments and siCav1 knockdown (n = Ctrl: 46, 29, 36; Rho+: 44, 41, 42; CL-A: 48, 40, 49; Y27: 61, 37, 46; ML7: 52, 38, 36; MβCD: 40, 24, 28; siCtrl: 46, 17, 22; siCav1: 46, 28, 21 cells for 15, 12, 7 μm microtracks). g Normalized PercevalHR ratio and 2-NBDG heatmap for cells of differing stiffness following treatment in 7 μm microtracks. h–j Normalized PercevalHR ratio as a function of cell stiffness (h), cell elongation (i), and track displacement (j) in 7 μm microtracks across cell stiffness altering treatments. k–m 2-NBDG uptake as a function of cell stiffness (k), cell elongation (l), and track displacement (m) in 7 μm microtracks across cell stiffness altering treatments. Data shown as mean ± s.e.m.; dashed lines show exponential growth (e, f, j, m); one-phase association (h, k), and one-phase decay (i, l); two-tailed Mann–Whitney test and extra sum-of-squares F-test for comparing curves (e, f); *P < 0.05, **P < 0.01. Scale bar, 15 μm
